Get the Stockscreener App
0.00
100.00%
-4.97
Bluebird Bio Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases.
See More
Previous Close:
$4.97
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$48.77M
Revenue:
$21.73M
Net Income/Loss:
$-91.17M
P/E Ratio:
0.00
EPS:
-0.74
Net Cash Flow:
$-286.43M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$15.40
Bluebird Bio Inc Stock (BLUE) Company Profile
Name
Bluebird Bio Inc
Sector
Industry
Phone
339-499-9300
Address
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Compare BLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
0.00 | 48.77M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-15-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-11-23 | Downgrade | HSBC Securities | Hold → Reduce |
| Dec-08-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-17-23 | Initiated | Cantor Fitzgerald | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-19-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-01-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-28-23 | Initiated | JP Morgan | Overweight |
| Mar-07-23 | Initiated | Robert W. Baird | Outperform |
| Aug-05-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-02-22 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-06-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-07-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-08-21 | Reiterated | Barclays | Equal Weight |
| Nov-08-21 | Reiterated | Canaccord Genuity | Hold |
| Nov-08-21 | Downgrade | Goldman | Neutral → Sell |
| Nov-08-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-08-21 | Reiterated | Wedbush | Neutral |
| Nov-08-21 | Reiterated | Wells Fargo | Equal Weight |
| Aug-10-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-10-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-10-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-10-21 | Resumed | William Blair | Mkt Perform |
| Aug-09-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Mar-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Feb-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-16-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-16-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-09-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-05-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-05-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Nov-05-20 | Downgrade | Stifel | Buy → Hold |
| Nov-02-20 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-20-20 | Initiated | Mizuho | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-27-20 | Upgrade | Stifel | Hold → Buy |
| Feb-19-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Feb-03-20 | Resumed | BofA/Merrill | Buy |
| Feb-03-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-13-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-19-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-01-19 | Initiated | Stifel | Hold |
| Aug-12-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-19 | Upgrade | Maxim Group | Hold → Buy |
View All
Bluebird Bio Inc Stock (BLUE) Latest News
Will earnings trigger a reversal in bluebird bio Inc.Quarterly Profit Report & Weekly Watchlist for Consistent Profits - newser.com
Should I hold or sell bluebird bio Inc. stock in 20252025 Volatility Report & Target Return Focused Stock Picks - Trung tâm Dự báo KTTV quốc gia
What Wall Street predicts for bluebird bio Inc. stock priceAnalyst Upgrade & AI Based Buy and Sell Signals - newser.com
Is bluebird bio Inc. stock a smart buy before Fed meetingJuly 2025 Market Mood & Detailed Earnings Play Strategies - Trung tâm Dự báo KTTV quốc gia
What technical signals suggest for bluebird bio Inc. stockJuly 2025 Retail & Daily Chart Pattern Signals - newser.com
Lobbying Update: $60,000 of GENETIX BIOTHERAPEUTICS INC. (FORMERLY BLUEBIRD BIO INC.) lobbying was just disclosed - Quiver Quantitative
Is bluebird bio Inc. stock supported by strong fundamentalsWeekly Risk Report & Entry Point Confirmation Signals - newser.com
Will bluebird bio Inc. see short term momentumInflation Watch & Real-Time Buy Signal Alerts - newser.com
Car T Cell Therapy For Multiple Myeloma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary - Barchart.com
United States Adrenoleukodystrophy Treatment Market - openPR.com
Pattern recognition hints at bluebird bio Inc. upsideMarket Sentiment Summary & Daily Price Action Insights - newser.com
The commercial real estate media source. - NEREJ
Regeneron backs bluebird with $100 mn, jointly work on cancer therapies - Entrepreneur India
Has bluebird bio Inc. formed a bullish divergenceJuly 2025 Short Interest & Fast Entry and Exit Trade Plans - newser.com
Analyzing recovery setups for bluebird bio Inc. investorsWeekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com
News impact scoring models applied to bluebird bio Inc.Market Sentiment Summary & Technical Entry and Exit Tips - newser.com
Will bluebird bio Inc. benefit from macro trendsWeekly Trade Report & Technical Confirmation Trade Alerts - newser.com
Will bluebird bio Inc. bounce back from current supportDay Trade & Low Risk Investment Opportunities - newser.com
Is bluebird bio Inc a good long term investmentRisk Management Strategies & Free Explosive Wealth Accumulation - earlytimes.in
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio LawsuitBLUE - MarketScreener
Chart based analysis of bluebird bio Inc. trends2025 Sector Review & Low Risk High Reward Ideas - newser.com
Is bluebird bio Inc. showing signs of accumulationForecast Cut & Short-Term Trading Alerts - newser.com
Former bluebird CEO picked to lead Inventiva - biocentury.com
What’s the recovery path for long term holders of bluebird bio Inc.Weekly Market Report & Low Volatility Stock Recommendations - newser.com
Gene Therapy for Rare Disease Market to Reach US$ 24.54 Bn by 2033, - openPR.com
Sickle Cell Disease Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Sanofi, Novartis AG, Bluebird Biotech, Pfizer Inc., Aruvant Sciences Inc - Barchart.com
Bluebird Bio Inc Stock (BLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):